{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"66"}],"units":"Participants"}],"description":"Complete response was assessed by the Cheson Response Criteria. Complete response is disappearance of all signs and symptoms of lymphoma for a period of at least one month. All lymph nodes and nodal masses must have regressed to normal size (1.5 cm in their greatest transverse diameter for nodes \\> 1.5 cm before therapy).","groups":[{"description":"Combination chemo and biological therapy\n\nRituximab: 2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5\n\nFilgrastim: Filgrastim day 6 until absolute neutrophil count (ANC) reaches 5000 after the nadir, every cycle\n\nEtoposide, prednisone, vincristine, cyclophosphamide and doxorubicin hydrochloride (EPOCH): combination chemotherapy: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles","id":"OG000","title":"Arm 1-Combination Chemo and Biological Therapy"}],"paramType":"NUMBER","populationDescription":"One participant declined to participate before treatment started, and one participant was not evaluable.","reportingStatus":"POSTED","timeFrame":"The participants were followed for an average of 6 months to determine response to therapy.","title":"Percentage of Participants With Complete Response","type":"SECONDARY","unitOfMeasure":"percentage of participants"}